Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
The company plans to enter the formulation business in January 2022. It has also opened a branch in Hyderabad to trade pharmaceutical chemicals
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
The segment delivered strong sales growth of 20% YoY
Subscribe To Our Newsletter & Stay Updated
